[Gilead Sciences](https://www.gilead.com)

June 30, 2026 (LOI evaluation cut-off)

Amount not specified; funding is competitive and depends on research scope and merit.

Supports research on AmBisome (liposomal amphotericin B) regarding safety, efficacy, and epidemiology in invasive fungal diseases, including novel dosing strategies and resistance trends.

--- ## Description Gilead Sciences is inviting Letters of Interest (LOIs) for research focused on AmBisome (liposomal amphotericin B) within the context of invasive fungal diseases. The aim is to advance the understanding of AmBisome’s safety, efficacy, and epidemiology, especially in populations such as patients with hematologic malignancies, critically ill ICU patients, and those with breakthrough infections after antifungal prophylaxis. The topic encourages studies on investigational dosing strategies (e.g., nebulized or intermittent administration), empirical (early) treatment, and multi-country evaluations of AmBisome’s role amid evolving resistance and environmental changes. Research outcomes are expected to inform clinical practice and improve management of invasive fungal infections. --- ## Due Dates - **June 30, 2026:** LOI evaluation cut-off date (LOIs received in Gilead OPTICS by this date will be evaluated) LOIs submitted after this date may not be considered under this specific AmBisome Topic of Interest. --- ## Funding Amount - **Award size:** Not specified; funding is competitive and based on the merit and scope of the research proposal. - **Duration:** Not specified; varies by project. --- ## Eligibility - Open to researchers and institutions with concepts relevant to AmBisome (liposomal amphotericin B) in invasive fungal disease. - Applicable patient populations include: - Patients with hematologic malignancies or disease - Critically ill ICU patients - Patients with breakthrough invasive fungal infections after antifungal prophylaxis - Studies involving investigational dosing strategies (e.g., nebulized or intermittent dosing) are of interest, but these uses are not approved by regulatory authorities. - Researchers must consider local product labels and the availability of liposomal amphotericin B in their setting. - No specific institutional or geographic restrictions are detailed, but applicants should consult their local Gilead medical representative regarding feasibility. --- ## Application Process - Submit a **Letter of Interest (LOI)** via [Gilead OPTICS](https://www.gilead.com/science/research/research-funding-programs/external-sponsored-research#esr), Gilead’s online proposal submission portal. - LOIs must clearly address one or more of the specified topic areas. - Only LOIs received by June 30, 2026, will be evaluated for this topic. - For questions related to local product use, label, or availability, contact your local Gilead medical representative. - For administrative or submission-related questions, use the contact options on the [External Sponsored Research](https://www.gilead.com/science/research/research-funding-programs/external-sponsored-research#esr) page or within the OPTICS portal. --- ## Additional Information - The use of AmBisome in investigational formats (e.g., nebulized or intermittent dosing) is not approved by regulatory authorities; safety and efficacy in these contexts have not been established. - Researchers should ensure that their proposals align with local regulations and product availability. - LOIs should be concise and directly address the research priorities outlined in the topic description. --- ## External Links - [AmBisome – Virology & Infectious Diseases RFP Topic of Interest](https://www.gilead.com/science/research/research-funding-programs/external-sponsored-research/virology-rfp-opportunities) - [Gilead OPTICS – Apply for Research Funding](https://www.gilead.com/science/research/research-funding-programs/external-sponsored-research#esr) - [Gilead Sciences Contact Page](https://www.gilead.com/contact-us) --- ## Contact Information | Purpose | Contact Details | |-------------------------------|-------------------------------------------------| | General inquiries | [grants@gilead.com](mailto:grants@gilead.com) | | Main phone (Gilead HQ) | +1 (650) 574 3000 | | Local product/label questions | Contact your local Gilead medical representative| ---

AmBisome – Virology & Infectious Diseases RFP Topic of Interest

Sign in to see full grant listing